Cns Pharmaceuticals Inc (NASDAQ:CNSP) currently has a daily average trading volume of 16.17M but it saw 16636531 shares traded in last market. With a market cap of 6.20M USD, the company’s current market price of $0.11 came rising about 3.85 while comparing to the previous closing price of $0.10. In past 52 weeks, the stock remained buoying in the range of price level as high as $23.90 and as low as $0.08. In the recent trading on the day, stock has struck highest price mark of $0.0919 while lowest mark touched by it was $0.1085.
Taking a look at 20-day trading activity of Cns Pharmaceuticals Inc (CNSP) gives us an average price of $0.1010, while its current price level is -99.55% below from 52-week high level whereas it is 29.10% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $0.1068 while that of 200 days or SMA-200 reads an average of $1.8086. A closer look into the stock’s movement over the week reveals that its volatility is standing at 16.78% during that period while stretching the period over a month that decreases to 11.44%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 53.47 which implies that the stock is in neutral territory.
Over the week, CNSP’s stock price is moving 17.43% up while it is 0.47% when we observe its performance for the past one month. Year-to-date it is -10.47% down and over the past year, the stock is showing a downside performance of -99.28%.
The company is expected to be releasing its next quarterly report in March, for which analysts forecasted an EPS of 0 while estimate for next year EPS is 0.
Currently, Cns Pharmaceuticals Inc’s total number of outstanding shares is 57.49M with 1.04% of that held by the insiders while 0.79% of its common stock has been owned by the institutions. Company’s return on investment (ROI) stands at -508.80% and return on equity (ROE) at -2116.75%. Stock’s beta reads 1.04. Stock has a price to book (P/B) ratio of 1.08. Its return on asset (ROA) is -350.34% on average.
